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1548Objective: The optimal treatment for chronic type B dissection remains controversial. This study reports early
and midterm results of thoracic endovascular aortic repair for chronic type B aortic dissection.
Methods: From June 2001 to September 2007, a total of 84 patients with chronic type B aortic dissection under-
went thoracic endovascular aortic repair. The time between onset of dissection and thoracic endovascular aortic
repair was 13.9 22.0 months (range, 1–120 months). All patients were followed up from 6 to 86 months (mean,
33.2  19.2 months).
Results: The entry tear was completely sealed in 77 cases (91.7%) during thoracic endovascular aortic repair.
The incidence of incomplete seal was 8.3%. The 1-month mortality was 1.2%. One patient had retrograde
type A dissection 1 month after the operation. Four patients underwent a second thoracic endovascular aortic
repair during follow-up, for endoleak in 3 patients and for newly formed intimal tear in 1 patient. Seven patients
(8.3%) died during follow-up. Three died of rupture of the thoracic aorta because of endoleak. The Kaplan–Meier
actuarial survival curve showed a 5-year survival of 84.4%. At 5 years, 75.2% of patients were alive with neither
endoleak nor reintervention.
Conclusions: Early and midterm results show that thoracic endovascular aortic repair was effective in the treat-
ment of chronic type B aortic dissection. Endoleak was the main cause of death during follow-up. With increased
surgical experience and refinement of the stent graft, results are likely to improve in the future. (J Thorac Cardi-
ovasc Surg 2010;139:1548-53)Since the introduction of endovascular repair of aortic
disease by Volodos and colleagues1 and Dake and associ-
ates,2 thoracic endovascular aortic repair (TEVAR) has
been increasingly used to treat type B aortic dissection. Clin-
ical trials have reported the efficacy of TEVAR for treatment
of type B dissection.3-5 Our own experience with TEVAR in
acute type B aortic dissection has been reported previously.6
Chronic type B dissection differs from acute type B dissec-
tion in many aspects. The outcome of TEVAR in treatment
of chronic type B dissection warrants a separate study,
because there is little information focusing on TEVAR for
chronic type B dissection. Between June 2001 and Septem-
ber 2007, a total of 84 patients with chronic type B aortic dis-
section underwent TEVAR at our center. The early and
midterm results are presented here.e Divisions of Cardiac Surgery,a Cardiology,b and Radiology,c Beijing Insti-
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The Journal of Thoracic and Cardiovascular SurMATERIALS AND METHODS
Patients
Eighty-four patients with chronic type B aortic dissection underwent TE-
VAR between June 2001 and September 2007. The study included 69 male
and 15 female patients, mean age 53.3  11.6 years (range, 32–78 years).
Inclusion criteria were as follows: (1) type B aortic dissection confirmed
by magnetic resonance angiography or computed tomographic angiography
(CTA) with patent false lumen and no intramural hematoma, (2) time be-
tween onset of dissection and admission longer than 1 month, (3) arch diam-
eter (landing zone) less than 38 mm, (4) adequate access route, and (5) no
aberrant right subclavian artery. From January 2005 onward, 2 more inclu-
sion criteria were added: (1) distance between entry tear and opening of left
subclavian artery (LSCA) more than 10 mm, (2) no Marfan syndrome or any
suspected connective tissue diseases. Informed consent was obtained from
each patient. The study was approved by the ethics committee of our center.
The patients’ clinical data are listed in Table 1. All TEVAR procedures were
elective, except for 3 emergency cases with contained rupture. The landing
zone diameter (healthy aortic segment proximal to the dissection, usually
the aortic arch where LSCA branches off) was measured with magnetic res-
onance angiography or CTA. Patients who were not suitable candidates for
TEVAR underwent surgical treatment. During the same period, 6 patients
with chronic type B dissection underwent surgery.
Stent Grafts
Five stent graft systems were used: Talent (Medtronic, Inc, Minneapo-
lis, Minn) in 33 cases, EndoFit (Lemaitre Vascular, Inc, Burlington, Mass)
in 1 case, Hercules (MicroPort, Shanghai, China) in 27 cases, Vasoflow
(Vascore, Suzhou, China) in 3 patients, and Grikin (Grikin Advanced
Materials Co, Ltd, Beijing, China) in 20 cases. All stent grafts had a metal
skeleton covered by polyester or polytetrafluoroethylene. The Grikin stent
graft does not have a longitudinal connecting bar, and the whole piece is
tapered.gery c June 2010
TABLE 1. Patients’ clinical data (N ¼ 84)
Sex (no.)
Male 69 (82.1%)
Female 15 (17.9%)
Age (y)
Range 32–78
Mean  SD 53.3  11.6
Symptoms (no.)
Back pain 61 (72.6%)
Shock 3 (3.6%)
Cause of aortic dissection (no.)
Hypertension 67 (79.8%)
Atherosclerosis 10 (11.9%)
Marfan syndrome 1 (1.2%)
Unknown 6 (7.1%)
Smoking (no.) 26 (31.0%)
Diabetes mellitus (no.) 9 (10.7%)
Contained rupture (no.) 3 (3.6%)
Maximum descending aortic dimension (mm)
Range 45–80
Mean  SD 58.1  9.8
Time from dissection to treatment (mo)
Range 1–120
Mean  SD 13.9  22.0
Abbreviations and Acronyms
CTA ¼ computed tomographic angiography
LSCA ¼ left subclavian artery
TEVAR ¼ thoracic endovascular aortic repair
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TEVAR was performed in a catheter operating theater by a team of
cardiovascular surgeons (S.D.X., F.J.H., J.F.Y., S.Y.), interventional cardi-
ologists (Z.Z.L.), radiologists (J.H.D.), and an anesthetist. General anesthe-
sia was used in 46 cases. Epidural anesthesia was used in 23 cases, and local
anesthesia in 15 cases. The TEVAR procedure has been described in detail
previously.6 In brief, the common femoral artery was exposed by surgical
dissection unilaterally. With the calibrated pigtail catheter, the distance be-
tween entry tear and the opening of the LSCA was measured. A stent graft
with a larger diameter (usually 10%–20% larger) was chosen. The delivery
sheath was introduced over a stiff guide wire to the appropriate position. Af-
ter the systolic blood pressure had been lowered to less than 100 mm Hg and
the heart rate lowered to less than 90 beats/min, the stent graft was deployed
under fluoroscopy. Figure 1 shows the digital subtraction angiogram of a pa-
tient with type B dissection before and after stent graft implantation. If the
entry tear was incompletely sealed, a cuff was added. Any reentry found in
the thoracic aorta was also sealed by adding a cuff or cuffs. Three stent grafts
were implanted in 1 patient, 2 stent grafts in 7 patients, and 1 stent graft in
the remaining 76 patients. The opening of the LSCA was totally covered by
the stent graft in 4 patients.
Postoperative Care
All patients were transferred to the intensive care unit after surgery. The
systolic blood pressure was lowered to less than 120 mm Hg by intravenous
drugs. Ventilatory assistance was withdrawn after each patient became fully
awake. Oral medication was given to control blood pressure. An intrave-
nous antibiotic was used for 3 postoperative days. No anticoagulants were
used. Most patients were ambulatory on postoperative day 1.
Follow-up
CTA was conducted before discharge and at least once a year after
surgery (Figure 2).
Statistical Analysis
Clinical data were collected in a database. All data are expressed as mean
 SD.
RESULTS
Early Results
The time between onset of dissection and TEVAR was
13.9  22.0 months (range, 1–120 months). Early results
are listed in Table 2. In 7 patients, the entry tear was incom-
pletely sealed. The incidence of endoleak was 8.3%. In
other patients, the entry tears were sealed completely by
the stent graft. One patient died of rupture of the thoracic
aorta on postoperative day 1, 8 hours after TEVAR. Just be-
fore death, the patient had nausea and vomited. The blood
pressure increased to 220/140 mm Hg and dropped suddenly
and dramatically, even before we tried to titrate up the nitro-
prusside. Thoracentesis confirmed left hemothorax. Sudden
rupture of the descending thoracic aorta was considered theThe Journal of Thoracic and Carcause of death. One-month mortality was 1.2%. Three
patients with contained rupture recovered smoothly. Two
of them underwent minithoracotomy to remove clots in the
chest cavity 1 week after the procedure. One of them
underwent thoracentesis to drain bloody fluid out of the
chest postoperatively. No neurologic defect followed the
procedure. LSCA was totally occluded in 4 patients. None
of these patients had left upper extremity ischemia or re-
duced cerebral blood supply. CTA before discharge showed
that the false lumen in the descending thoracic aorta was par-
tially thrombosed in the 7 patients with endoleaks. In the
other patients, the false lumen in the descending thoracic
aorta was totally thrombosed.
Midterm Results
All patients were followed up from 6 to 86 months (mean,
33.2  19.2 months). One patient had a retrograde type A
dissection 1 month after TEVAR. Emergency replacement
of the ascending aorta and arch was conducted.
Three of the 7 patients with endoleaks underwent a second
TEVAR procedure. A cuff was added at the proximal end of
the first stent graft, and the entry tear was totally sealed. The
other 4 patients with endoleaks all had entry tears immedi-
ately distal to the opening of the LSCA. Although the open-
ing of the LSCA was used as the landing zone and was
partially or totally covered in these 4 patients, a small
amount of blood still entered the false lumen through the en-
try tear. These patients refused open surgery. Three died of
rupture of the descending thoracic aorta during follow-up.
One remains alive under close supervision.diovascular Surgery c Volume 139, Number 6 1549
FIGURE 1. Digital subtraction angiogram of patient with type B dissection during thoracic endovascular aortic repair before (A) and after (B) stent graft
implantation.
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a newly formed intimal tear caused by the distal end of the
stent graft (Figure 3).
Mortality
In total, 7 patients died within the follow-up period.
Mortality during follow-up was 8.3%. Three patients with
endoleaks died of rupture of the thoracic aorta. One patient
with Marfan syndrome died of rupture of the abdominal
aorta caused by continuous dilation of the abdominal aorta.FIGURE 2. A, Magnetic resonance angiogram before thoracic endovascular aor
aortic repair.
1550 The Journal of Thoracic and Cardiovascular SurTwo patients died of diseases unrelated to aortic dissection,
1 of cancer and the other of complications of diabetes. One
patient died of an unknown cause. The Kaplan–Meier
actuarial survival curve showed a 5-year survival of
84.4% (Figure 4). At 5 years, 75.2% of patients were alive
with neither endoleak nor reintervention (Figure 5).
DISCUSSION
There is still controversy regarding the optimal treatment
for type B aortic dissection. Traditional treatment includestic repair. B, Computed tomographic angiogram after thoracic endovascular
gery c June 2010
TABLE 2. Early results (N ¼ 84)
Mortality (no.) 1 (1.2%)
Incomplete seal (no.) 7 (8.3%)
Renal insufficiency (no.) 2 (4.5%)
Fever (>38.0C, no.) 47 (56.0%)
Back pain (no.) 52 (61.9%)
Operative time (h, mean  SD) 2.5  0.3
Blood loss (mL, mean  SD) 86  6.5
Hospital stay (d, mean  SD) 10  2.0
Xu et al Acquired Cardiovascular Disease
A
C
Dmedical treatment of uncomplicated dissection and surgical
treatment of complicated dissection; however, surgery car-
ries high morbidity and mortality.7 Good long-term outcome
of medical treatment has been reported by some authors8;
however, the results of other studies have not been so fa-
vorable. Mortality among patients who survive to hospital
discharge with acute type B aortic dissection is high, ap-
proaching 1 in every 4 patients at 3 years.9 More and more
evidence has shown a patent false lumen to be an indepen-
dent risk factor for aortic enlargement and rupture during
follow-up. Continuing enlargement of aorta has been noted
during the chronic phase.10,11 Some authors have pointed
out that if the maximum aortic diameter is less than
45 mm at the onset of the dissection, the chance of later en-
largement is small12; others, however, have argued that
small aortic diameter (<40 mm) does not lessen the chance
of future enlargement.10 Thus, although it is not a current
practice in all centers, we have made it a policy to treat allFIGURE 3. Patient with new intimal tear during follow-up. A, New intimal te
repair. B, Second stent graft was added at distal end of first one.
The Journal of Thoracic and Carpatients with chronic type B dissection with a patent false
lumen. Our experience with TEVAR for acute type B dissec-
tion showed a 4-year survival of 89.4%. A 5-year survival of
84.4% with TEVAR for chronic type B dissection is
reported in this study. Both survivals are better than with tra-
ditional therapy. TEVAR for treatment of Type B dissection
is still in its infancy, however, and many factors remain
unresolved, such as the proper indication, anatomic require-
ment, choice of stent graft, and anesthesia.
Aortic dissections are divided into 3 phases in our center:
acute (<2 weeks), subacute (2 weeks–1 month), and chronic
(>1 month). A 1-month interval was used to discriminate
chronic dissection from acute dissection. After 1 month,
both the adventitia and dissected intima, which are fragile
in the acute phase, become fibrotic. Kato and coworkers4
share this opinion with us.
One patient with a huge false lumen aneurysm (6 cm in
diameter) and a large reentry in the abdominal aorta near
the diaphragm died suddenly on postoperative day 1.
Sudden rupture of the descending thoracic aorta was con-
firmed by thoracentesis. The primary entry tear near the
LSCA was sealed completely during TEVAR. The reentry
in the abdominal aorta was left untreated. Before TEVAR,
the false lumen had an entry and a reentry. After TEVAR,
the reentry became an entry, and there was no longer any
outlet. The blood pressure in the false lumen therefore
increased.13 The elevation of the blood pressure in the false
lumen was considered the cause of the rupture. The windowar caused by distal end of stent graft after first thoracic endovascular aortic
diovascular Surgery c Volume 139, Number 6 1551
FIGURE4. Kaplan–Meier survival curve shows 5-year survival of 84.4%.
FIGURE 5. Kaplan–Meier curve shows freedom from death, endoleak,
and reintervention at 7 years of 75.2%.
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lumen is a dangerous period that may last from minutes or
hours to several weeks. High blood pressure, a large false lu-
men, a large reentry, and a short distance between the entry
and reentry are considered risk factors for false lumen rup-
ture during this window phase. After our experience with
this patient, patients were sedated for at least 24 hours after
TEVAR. Blood pressure was strictly controlled. Any reentry
in the descending thoracic aorta was sealed by adding a cuff
or cuffs (short stent graft) during TEVAR. Fortunately, with
these measures, no more sudden deaths within a short time
after TEVAR occurred.
Seven of 84 patients in our group had incomplete seal of
the entry tear. The incidence of endoleak was 8.3%, which
was similar to that in Kim and colleagues’ study.14 Partial
thrombosis of the false lumen was observed in all 7 of the
patients with incomplete seals. Three of these patients under-
went a second TEVAR procedure. At first, partial thrombo-
sis of the false lumen was considered to be better than
a patent false lumen. That 3 of 4 patients without any further
treatment would eventual die of rupture of the descending
thoracic aorta was not anticipated. The cause of the rupture
may have been that partial thrombosis of the false lumen led
to the occlusion of the distal tear. The outflow of the false
lumen was impeded or totally occluded, resulting in eleva-
tion of the blood pressure in the false lumen and eventually
rupture of the false lumen. Tsai and coworkers15 concluded
from the International Registry of Acute Aortic Dissection
study that patients with a partially thrombosed false lumen
had a worse prognosis than did those with a patent false
lumen. This is similar to what we found in our study.
Because the prognosis of the endoleak is poor, all efforts
to avoid it should be made. The shorter the distance between
the opening of the LSCA and the entry tear, the greater the
chance of an endoleak. In the later period of this study,1552 The Journal of Thoracic and Cardiovascular Suranother inclusion criterion for TEVAR was added, that the
distance between the entry tear and the opening of the
LSCA be no less than 10 mm. From then on, endoleak
was avoided. For those patients in whom the entry tear is
closer to the LSCA, surgical treatment is the recommended
option.
One patient with Marfan syndrome died of rupture of the
abdominal aorta caused by continuous dilation of the
abdominal aorta. Since then, TEVAR has no longer been
used for patients with Marfan syndrome or any connective
tissue diseases. Replacement of the diseased aorta with
a vascular graft is the choice for these patients.
One patient had retrograde type A aortic dissection
1 month after TEVAR. This serious complication of
TEVAR has been reported previously.16,17 The causes of
type A dissection have been discussed in our previous arti-
cle.18 The new intimal tear was located at the proximal
end of the stent graft and may have been caused by the
bare spring. The more rigid the stent graft, the greater the
chance of a new intimal tear. Now flexible stent grafts (with-
out a longitude strut) are used for TEVAR for aortic dissec-
tion in our center. When the whole piece is flexible, the
proximal bare spring becomes less harmful.
In TEVAR for aortic dissection, the size of the stent graft
is determined by the diameter of the proximal landing zone
(usually the aortic arch). After deployment, the proximal
portion of the stent graft anchors in the intact aortic arch,
and the distal portion anchors in the true lumen of the dis-
sected descending aorta. In the early period of the study,
we did not have any domestic stent grafts. Talent and Endo-
Fit were our only choices for TEVAR; however, both of
these were designed for true aneurysm rather thangery c June 2010
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follow-up, some patients returned with a significant dilated
descending aorta caused by dilatation of the distal part of
the stent graft. One patient even had a new intimal tear
caused by dilatation of the distal end of the stent graft
(Figure 3). An aneurysm or a new tear at the end of the stent
graft has been previously reported by others.17,19 We sus-
pected that there might have been a significant difference
in diameter between the arch and the true lumen in the de-
scending aorta. The taper ratio between the arch and the
true lumen in the descending aorta has been studied.20 The
taper ratio is defined as [(Arch F  True lumen F)/Arch
F]$100% (F: diameter). The study showed a taper ratio of
30% in chronic dissection. If a stent graft without a tapered
design and 15% larger than the aortic arch is selected, its dis-
tal end will exceed the true lumen of the descending aorta by
more than 60%. This would explain the excessive dilatation
of the descending aorta and the new intimal tears during fol-
low-up.
Domestic stent grafts were available later in the study.
Since then, a tapered stent graft (proximal end 6 mm larger
than distal end) has been used in TEVAR for aortic dissec-
tion, and none of patients so treated had any obvious dilata-
tion of the descending aorta during follow-up.
Effective analgesia and steady blood pressure control
are keys to the success of the procedure. In the beginning,
general anesthesia was used. A smooth process could be
achieved, and the blood pressure was easy to control.
Then a patient with a pseudoaneurysm had a cerebral infarc-
tion during TEVAR, and we were unable to determine when
it occurred. We realized that the patient’s conscious state
should be monitored during the process, and we switched
to epidural and local anesthesia. When epidural anesthesia
was used, some anesthesiologists were concerned about epi-
dural hematoma. Finally, local anesthesia was chosen during
TEVAR. Apart from the conscious state, another benefit was
found to this in that the spinal cord function could also be
monitored during the procedure.
The limitations of this study are obvious. It is a retrospec-
tive, uncontrolled study. During the study, the inclusion
criteria were changed. Some stent grafts were used in the
early period of the study but abandoned later. Although
the longest follow-up is 7 years, the mean follow-up is not
quite 3 years. All these limitations are explained in part by
the newness and fast development of this novel technique.
Further investigations are required in the future, but we are
optimistic about TEVAR. We believe that, with refinement
of the stent graft and increased surgical experience, TEVAR
has the potential to become the first choice for aortic dis-
section.
CONCLUSIONS
Early and midterm results showed TEVAR to be effective
for the treatment of chronic type B aortic dissection.The Journal of Thoracic and CarEndoleak was the main cause of death during follow-up.
A flexible and tapered stent graft may be more suitable for
aortic dissection. With increased surgical experience and
refinement of the stent graft, better outcomes are expected.
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